Viatris Innovation GmbH
Clinical trials sponsored by Viatris Innovation GmbH, explained in plain language.
A German subsidiary of Viatris, a global healthcare company making generic and branded medicines.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New blood thinner tested in small chinese heart study Results expected Oct 2026 (estimated)
- New lupus pill shows promise in major trial Results expected Dec 2026 (estimated)
- New pill could tame lupus flares in major trial Results expected Mar 2027 (estimated)
- Could a Pen-Sized shot stop a heart attack in its tracks? Results expected Jul 2027 (estimated)
-
New pill could tame lupus flares in major trial
Disease control OngoingThis phase 3 trial tests whether adding cenerimod, a daily pill, to standard lupus treatments can reduce symptoms in adults with moderate-to-severe systemic lupus erythematosus (SLE). About 470 participants will receive either cenerimod or a placebo for 12 months. Researchers wil…
Phase 3 • Sponsor: Viatris Innovation GmbH • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New lupus pill shows promise in major trial
Disease control OngoingThis Phase 3 study tests whether adding cenerimod to standard lupus treatments can better control moderate-to-severe lupus symptoms. About 451 adults will receive either cenerimod or a placebo for 12 months. The main goal is to see if more people improve on a lupus disease activi…
Phase 3 • Sponsor: Viatris Innovation GmbH • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New lupus drug tested for Long-Term safety in 680 patients
Disease control By invitation onlyThis study looks at the long-term safety of cenerimod in adults with moderate-to-severe lupus. About 680 participants who were in a previous study will take cenerimod for up to 3 years, along with their usual lupus medications. Researchers will track side effects and see how well…
Phase 3 • Sponsor: Viatris Innovation GmbH • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Could a Pen-Sized shot stop a heart attack in its tracks?
Disease control By invitation onlyThis study tests a drug called selatogrel, which people inject themselves at the first sign of a heart attack. The goal is to see if it can prevent death or reduce heart damage. The trial involves 25,000 people who recently had a heart attack and have other risk factors. Particip…
Phase 3 • Sponsor: Viatris Innovation GmbH • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC